A review published in JAMA Cardiology on Wednesday has identified situations in which the transcatheter aortic valve replacement (TAVR) devices sold by Boston Scientific, Edwards Lifesciences and Medtronic may have slight advantages over each other.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,